Oxford University Press

SHERPA: Yellow

People

  1. Janjigian
    Janjigian
  2. Ku
    Ku
  3. Ilson
    Ilson
  4. Molena
    Molena
  5. Schultz
    Schultz
  6. Stadler
    Stadler
  7. Gerdes
    Gerdes
  8. Jones
    Jones
  9. Kelsen
    Kelsen
  10. Lumish
    Lumish

Groups

  1. Department of Medicine (38)
  2. Gastrointestinal Oncology Service (38)
  3. Solid Tumor Oncology Division (38)
  4. Center for Pancreatic Cancer Research (8)
  5. Surgery (8)
  6. GSK Faculty (7)
  7. Epidemiology and Biostatistics (6)
  8. GME, Medicine (6)
  9. Graduate Medical Education (6)
  10. Hematologic Malignancies, Division of (6)
Search Within
  1. "Yelena Janjigian"
Formats
  1. Meeting Abstract (32)
  2. Journal Article (5)
  3. Editorial (1)
Groups
  1. Department of Medicine (38)
  2. Gastrointestinal Oncology Service (38)
  3. Solid Tumor Oncology Division (38)
  4. Center for Pancreatic Cancer Research (8)
  5. Surgery (8)
  6. GSK Faculty (7)

More Groups

People
  1. Yelena Janjigian (38)
  2. Daniela Molena (6)
  3. Geoffrey Ku (6)
  4. David Ilson (5)
  5. Laura Tang (4)
  6. Melissa Lumish (4)

More People

Years
  1. 2024 (1)
  2. 2023 (5)
  3. 2022 (7)
  4. 2021 (9)
  5. 2020 (4)
  6. 2019 (3)

More Years

Publications
  1. Annals of Oncology (36)
  2. JNCI: Journal of the National Cancer Institute (2)

Results (38)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer
    Journal Article

    Lumish, M. A.; Walch, H.; Maron, S. B.; Chatila, W.; Kemel, Y.; Maio, A.; Ku, G. Y.; Ilson, D. H.; Won, E.; Li, J.; more...
    JNCI: Journal of the National Cancer Institute (2024)

    Fulltext@MSK | Save
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Oh, D. Y.; Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Omori, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Yanez Weber, P. E.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Oh, D. Y.; Omori, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
    Meeting Abstract

    Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Weber, P. E. Y.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: Substudies in gastric and colorectal cancer
    Meeting Abstract

    Oaknin, A.; Meric-Bernstam, F.; Lang, J.; Ciombor, K.; Ray-Coquard, I.; Oza, A.; Yonemori, K.; Xu, R.; Zhao, J.; Gajavelli, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
    Meeting Abstract

    Cytryn, S.; Joshi, S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; Rao, D.; Goldberg, Z.; Sugarman, R.; Antoine, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • First-line lenvatinib (Len) plus pembrolizumab (Pembro) plus chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in
    Meeting Abstract

    Shitara, K.; Ben-Aharon, I.; Rojas, C.; Eyzaguirre, D. A. A.; Hubert, A.; Moya, H. A.; Cohen, D.; Bai, L. Y.; Ghiringhelli, F.; Wyrwicz, L.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial
    Meeting Abstract

    Janjigian, Y.; Rha, S.; Oh, D.; Díez García, M.; van Laarhoven, H.; Chao, Y.; Di Bartolomeo, M.; Haj Mohammad, N.; Zhong, W.; Croydon, E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Novel frailty index predicts short-term outcomes after esophagectomy in elderly patients with esophageal cancer
    Meeting Abstract

    Boerner, T.; Tin, A.; Vickers, A.; Harrington, C.; Janjigian, Y.; Ilson, D.; Wu, A.; Bott, M.; Isbell, J.; Park, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save